Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes

Neurology

Volumn 74, Issue 18, 2010, Pages 1416-1423

  Gilman, S ^a   Koeppe, R A ^b   Nan, B ^c   Wang, C N ^c   Wang, X ^c   Junck, L ^a   Chervin, R D ^a   Consens, F ^a   Bhaumik, A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PIPERIDINYLPROPIONATE C 11; ACETYLCHOLINESTERASE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; AMYGDALOID NUCLEUS; ARTICLE; BRAIN SCINTISCANNING; CEREBELLUM; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CORPUS STRIATUM; FEMALE; HIPPOCAMPUS; HUMAN; MALE; PARKINSON DISEASE; PONS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RADIOISOTOPE DISTRIBUTION; SHY DRAGER SYNDROME; THALAMUS;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; AGED; AGED, 80 AND OVER; BRAIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NEURAL PATHWAYS; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 77951772295     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181dc1a55     Document Type: Article

References (40)

1. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
2. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219:1184-1190.
3. Whitehouse PJ, Hedreen JC, White CL 3rd, Price DL. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983;13:243-248.
4. Candy JM, Perry RH, Perry EK, et al. Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. J Neurol Sci 1983;59:277-289.
5. Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff 's Disease. Acta Neuro-pathol 1983;61:101-108.
6. Irie T, Fukushi K, Akimoto Y, Tamagami H, Nozaki T. Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AChE) in vivo. Nucl Med Biol 1994;21:801-808.
7. Irie T, Fukushi K, Namba H, et al. Brain acetylcholinest-erase activity: validation of a PET tracer in a rat model of Alzheimer's disease. J Nucl Med 1996;37:649-655.
8. Kilbourn MR, Snyder SE, Sherman PS, Kuhl DE. In vivo studies of acetylcholinesterase activity using a labeled substrate, N-[11C]methylpiperdin- 4-yl propionate ([11C]PMP). Synapse 1996;22:123-131.
9. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996;40:399-410.
10. Kuhl DE, Koeppe RA, Minoshima S, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999;52:691-699.
11. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomo-graphic study. Arch Neurol 2003;60:1745-1748.
12. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006; 253:242-247.
13. Lange KW, Wells FR, Jenner P, Marsden CD. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J Neuro-chem 1993;60:197-203.
14. Shinotoh H, Namba H, Yamaguchi M, et al. Positron emission tomographic measurement of acetylcholinester-ase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranu-clear palsy. Ann Neurol 1999;46:62-69.
15. Fujita M, Ichise M, Zoghbi SS, et al. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann Neurol 2006;59:174-177.
16. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
17. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670-676.
18. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
19. Koeppe RA, Frey KA, Snyder SE, Meyer P, Kilbourn MR, Kuhl DE. Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brain. J Cereb Blood Flow Metab 1999;19:1150-1163.
20. Snyder SE, Tluczek L, Jewett DM, Nguyen TB, Kuhl DE, Kilbourn MR. Synthesis of 1-[11C]methylpiperidin-4-yl pro-pionate ([11C]PMP) for in vivo measurements of acetylcho-linesterase activity. Nucl Med Biol 1998;25:751-754.
21. Zubieta JK, Koeppe RA, Mulholland GK, Kuhl DE, Frey KA. Quantification of muscarinic cholinergic receptors with [11C]NMPB and positron emission tomography: method development and differentiation of tracer delivery from receptor binding. J Cereb Blood Flow Metab 1998; 18:619-631.
22. Minoshima S, Koeppe RA, Mintun MA, et al. Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med 1993; 34:322-329.
23. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994;35:1528-1537.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
25. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983;106:257-270.
26. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991; 114:2095-2122.
27. Jacobs DM, Marder K, Cote LJ, Sano M, Stern Y, Mayeux R. Neuropsychological characteristics of preclinical dementia in Parkinson's disease. Neurology 1995;45:1691-1696.
28. Troster AI, Stalp LD, Paolo AM, Fields JA, Koller WC. Neu-ropsychological impairment in Parkinson's disease with and without depression. Arch Neurol 1995;52:1164-1169.
29. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997;244:2-8.
30. Gotham AM, Brown RG, Marsden CD. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off ' levodopa. Brain 1988;111:299-321.
31. Stern Y, Mayeux R, Rosen J, Ilson J. Perceptual motor dysfunction in Parkinson's disease: a deficit in sequential and predictive voluntary movement. J Neurol Neurosurg Psychiatry 1983;46:145-151.
32. Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984;15:415-418.
33. Tagliavini F, Pilleri G, Bouras C, Constantinidis J. The basal nucleus of Meynert in idiopathic Parkinson's disease. Acta Neurol Scand 1984;70:20-28. (Pubitemid 14085616)
34. Rogers JD, Brogan D, Mirra SS. The nucleus basalis of Meynert in neurological disease: a quantitative morphological study. Ann Neurol 1985;17:163-170.
35. Jenkinson N, Nandi D, Muthusamy K, et al. Anatomy, physiology, and pathophysiology of the pedunculopontine nucleus. Mov Disord 2009;24:319-328.
36. Winn P. How best to consider the structure and function of the pedunculopontine tegmental nucleus: evidence from animal studies. J Neurol Sci 2006;248:234-250.
37. Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurode-generative disease. Brain 2007;130:2770-2788.
38. Schmeichel AM, Buchhalter LC, Low PA, et al. Mesopontine cholinergic neuron involvement in Lewy body dementia and multiple system atrophy. Neurology 2008;70:368-373.
39. Jaarsma D, Ruigrok TJ, Caffe R, et al. Cholinergic inner-vation and receptors in the cerebellum. Prog Brain Res 1997;114:67-96.
40. Hirano S, Shinotoh H, Arai K, et al. PET study of brain acetylcholinesterase in cerebellar degenerative disorders. Mov Disord 2008;23:1154-1160.